Four Houston entrepreneurs have teamed up to create a program based on each of their expertise that provides a launch pad for aspiring startup founders. Getty Images

For some aspiring startup founders, the biggest thing holding them back is not knowing where to start. A group of former founders and mentors are teaming up to create that first step.

"A few months ago it struck me that maybe there was a gap in the market between the aspiring entrepreneur," says Steve Jennis, "and the accelerator or incubator program."

Jennis, who's a founder, consultant, and mentor in Houston, tapped a few of his fellow founder-mentors to create Founder's Compass, an online masterclass for people who have a business idea but don't know what to do next. Along with Jennis, founder of JCG and PrismTech, the program was created by Brittany Barreto, founder of Pheramor and Femtech Focus; Leela Madan, founder of Madan Law; and Catherine Brown, founder of ExtraBold Sales.

"We thought that the four of us could put together a masterclass comprising of four modules — each module relates to the skill set that we are individually bringing," Jennis tells InnovationMap. "All together, we're representing a framework for new entrepreneurs to get a kickstart to their business and help them with the next step of their journey — whatever that may be."

The four modules will be presented in virtual, interactive classes lasting three hours each and offered in two different ways each month. Students can register for a two-day option — six hours on a Friday followed by another six hours on a Saturday — or a four-week option — three hours on a weeknight once a week for four weeks.

The four modules will cover the following:

  • Validating your business concept and MVP product-market fit (led by Jennis)
  • Customer development, feedback, and target market definition (led Brown)
  • Protecting your intellectual property and managing your business risk (led by Madan)
  • Engaging with the innovation ecosystem and preparing to fundraise (led by Barreto)
Jennis says the program is not intended to be competitive with accelerators, rather Founder's Compass can act as a feeder into these programs. This is why, Jennis says, the masterclass is set up to be relatively cheap at $100 an hour — or $1,200 for the full program.
"We wanted something that was much more convenient, readily available, and easily affordable, so that's why we settled on the two-day or four-evening format to give people something that they didn't have to think about for months," Jennis says. "We saw an opportunity here — not just to be another accelerator — but to be something for people in the game."

Registration for Founder's Compass is open now for September and October, and participants who sign up before August 1 will receive half off — making the course just $600.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”